|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Portal vein thrombosis in liver cirrhosis显示文摘Portal vein thrombosis(PVT) is considered to be a frequent complication of liver cirrhosis. However, unlike PVT in patients without cirrhosis, very few data are available on the natural history and management of PVT in cirrhosis, despite its association with potentially life-threatening conditions, such as gastroesophageal bleeding and acute intestinal ischemia. Moreover, no consensus regarding PVT in cirrhosis exists. Suggested causes of PVT in cirrhosis include reduced portal blood flow velocity, multiple congenital or acquired thrombophilic factors, inherited or acquired conditions, and derangement of liver architecture. However, the understanding of PVT in cirrhosis is incomplete. In addition, information on the management of PVT in cirrhosis is inadequate. The aims of this review are to:(1) assemble data on the physiopathological mechanism, clinical findings, diagnosis and management of PVT in cirrhosis;(2) describe the principal factors most frequently involved in PVT development; and(3) summarize the recent knowledge concerning diagnostic and therapeutic procedures. | Nao Kinjo Hirofumi Kawanaka Tomohiko Akahoshi Yoshi-hiro Matsumoto Masahiro Kamori Yoshihiro Nagao Naotaka Hashimoto Hideo Uehara Morimasa Tomikawa Ken Shirabe Yoshihiko Maehara | 2014 | World Journal of Hepatology2014，6，2： | 38 |
| 2 | Management of thrombocytopenia due to liver cirrhosis:A review显示文摘Thrombocytopenia is a common complication in liver disease and can adversely affect the treatment of liver cirrhosis,limiting the ability to administer therapy and delaying planned surgical/diagnostic procedures because of an increased risk of bleeding.Multiple factors,including splenic sequestration,reduced activity of the hematopoietic growth factor thrombopoietin,bone marrow suppression by chronic hepatitis C virus infection and anti-cancer agents,and antiviral treatment with interferon-based therapy,can contribute to the development of thrombocytopenia in cirrhotic patients.Of these factors,the major mechanisms for thrombocytopenia in liver cirrhosis are(1)platelet sequestration in the spleen;and(2)decreased production of thrombopoietin in the liver.Several treatment options,including platelet transfusion,interventional partial splenic embolization,and surgical splenectomy,are now available for severe thrombocytopenia in cirrhotic patients.Although thrombopoietin agonists and targeted agents are alternative tools for noninvasively treating thrombocytopenia due to liver cirrhosis,their ability to improve thrombocytopenia in cirrhotic patients is under investigation in clinical trials.In this review,we propose a treatment approach to thrombocytopenia according to our novel concept of splenic volume,and we describe the current management of thrombocytopenia due to liver cirrhosis. | Hiromitsu Hayashi Toru Beppu Ken Shirabe Yoshihiko Maehara Hideo Baba | 2014 | World Journal of Gastroenterology2014，20，10： | 19 |
| 3 | Preoperative sorting of circulating T lymphocytes in patients with esophageal squamous cell carcinoma: Its prognostic significance显示文摘AIM: To elucidate the immunologic parameters for the outcome of patients with malignant tumors, especially esophageal squamous cell carcinoma (ESCC) associated with high malignant potential. METHODS: Clinicopathologic features were compared between patients with lower and higher CD4 and CD8 values as well as CD4/CD8 ratio in peripheral blood. RESULTS: The survival rate of patients with higher CD4 value was significantly better than that in patients with lower CD4 value (P = 0.039). The survival rate of patients with higher CD8 value was significantly worse than that of patients with lower CD8 value (P = 0.026). Similarly, the survival rate of patients with higher CD4/ CD8 ratio was significantly better than that of patients with lower CD4/CD8 ratio (P = 0.042). Additionally, multivariate analysis demonstrated that lower CD8 and lower CD4/CD8 ratio were factors independently associated with worse prognosis of patients. CONCLUSION: All the immunologic parameters can predict the outcome of patients with ESCC. | Tadahiro Nozoe Yoshihiko Maehara Keizo Sugimachi | 2005 | World Journal of Gastroenterology2005，11，42： | 18 |
| 4 | Dietary polyphenols and colorectal cancer risk:The Fukuoka colorectal cancer study显示文摘AIM:To investigate the associations between dietary intake of polyphenols and colorectal cancer. METHODS:The study subjects were derived from the Fukuoka colorectal cancer study, a community-based case-control study. The study subjects were 816 cases of colorectal cancer and 815 community-based controls. The consumption of 148 food items was assessed by a computer-assisted interview. We used the consumption of 97 food items to estimate dietary intakes of total, tea and coffee polyphenols. The Phenol-Explorer database was used for 92 food items. Of the 5 foods which were not listed in the Phenol-Explorer Database, polyphenol contents of 3 foods (sweet potatoes, satoimo and daikon) were based on a Japanese study and 2 foods (soybeans and fried potatoes) were estimated by ORAC-based polyphenol contents in the United States Department of Agriculture Database. Odds ratios (OR) and 95%CI of colorectal cancer risk according to quintile categories of intake were obtained by using logistic regression models with adjustment for age, sex, residential area, parental history of colorectal cancer, smoking, alcohol consumption, body mass index 10 years before, type of job, leisure-time physical activity and dietary intakes of calcium and n-3 polyunsaturated fatty acids.RESULTS:There was no measurable difference in total or tea polyphenol intake between cases and controls, but intake of coffee polyphenols was lower in cases than in controls. The multivariate-adjusted OR of colorectal cancer according to quintile categories of coffee polyphenols (from the first to top quintile) were 1.00 (referent), 0.81 (95%CI:0.60-1.10), 0.65 (95%CI:0.47-0.89), 0.65 (95%CI:0.46-0.89) and 0.82 (95%CI:0.60-1.10), respectively (P trend = 0.07). Similar, but less pronounced, decreases in the OR were also noted for the third and fourth quintiles of total polyphenol intake. Tea polyphenols and non-coffee polyphenols showed no association with colorectal cancer risk. The sitespecific analysis, based on 463 colon cancer cases and 340 rectal cancer cases, showed an inverse association between coffee polyphenols and colon cancer. The multivariate-adjusted OR of colon cancer for the first to top quintiles of coffee polyphenols were 1.00 (referent), 0.92 (95%CI:0.64-1.31), 0.75 (95%CI:0.52-1.08), 0.69 (95%CI:0.47-1.01), and 0.68 (95%CI:0.46-1.00), respectively (P trend = 0.02). Distal colon cancer showed a more evident inverse association with coffee polyphenols than proximal colon cancer. The association between coffee polyphenols and rectal cancer risk was U -shaped, with significant decreases in the OR at the second to fourth quintile categories. There was also a tendency that the OR of colon and rectal cancer decreased in the intermediate categories of total polyphenols. The decrease in the OR in the intermediate categories of total polyphenols was most pronounced for distal colon cancer. Intake of tea polyphenols was not associated with either colon or rectal cancer. The associations of coffee consumption with colorectal, colon and rectal cancers were almost the same as observed for coffee polyphenols. The trend of the association between coffee consumption and colorectal cancer was statistically significant. CONCLUSION:The present findings suggest a decreased risk of colorectal cancer associated with coffee consumption. | Zhen-Jie Wang Keizo Ohnaka Makiko Morita Kengo Toyomura Suminori Kono Takashi Ueki Masao Tanaka Yoshihiro Kakeji Yoshihiko Maehara Takeshi Okamura Koji Ikejiri Kitaroh Futami Takafumi Maekawa Yohichi Yasunami Kenji Takenaka Hitoshi Ichimiya Reiji Terasaka | 2013 | World Journal of Gastroenterology2013，19，17： | 12 |
| 5 | Prognosis of hepatocellular carcinoma accompanied by microscopic portal vein invasion显示文摘AIM:To investigate the prognostic factors in patients with hepatocellular carcinoma(HCC) accompanied by microscopic portal vein invasion(PVI).METHODS:Of the 267 patients with HCC undergoing hepatic resection at Aso Iizuka Hospital,71 had PVI.After excluding 16 patients with HCC that invaded the main trunk and the first and second branches of the portal vein,55 patients with microscopic PVI were enrolled.RESULTS:The patients with HCC accompanied by microscopic invasion were divided into two groups:solitary PVI(PVI-S:n = 44),and multiple PVIs(PVI-M:n = 11).The number of portal vein branches invaded by tumor thrombi was 5.4 ± 3.8(2-16) in patients with PVI-M.In cumulative survival,PVI-M was found to be a significantly poor prognostic factor(P = 0.0019);while PVI-M and non-anatomical resection were significantly poor prognostic factors in disease-free survival(P = 0.0213,and 0.0115,respectively).In patients with PVI-M,multiple intrahepatic recurrence was more common than in the patients with PVI-S(P = 0.0049).In patients with PVI-S,non-anatomical resection was a significantly poor prognostic factor in disease-free survival(P = 0.0370).Operative procedure was not a significant prognostic factor in patients with PVI-M.CONCLUSION:The presence of PVI-M was a poor prognostic factor in patients with HCC,accompanied by microscopic PVI.Anatomical resection is recommended in these patients with HCC.Patients with HCC and PVI-M may also be good candidates for adjuvant chemotherapy. | Ken Shirabe Kiyoshi Kajiyama Norifumi Harimoto Hideaki Masumoto Tatsuro Fukuya Masafumi Ooya Yoshihiko Maehara | 2009 | World Journal of Gastroenterology2009，15，21： | 10 |
| 6 | Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer显示文摘Postoperative recurrence occurs in approximately half of patients with non-small cell lung cancer(NSCLC), even after complete resection. Disease recurrence after surgical resection reduces the patient's life expectancy sharply. The prognosis after postoperative recurrence is considered to largely depend on both the mode of first recurrence(distant, locoregional or combined) and the treatment modality:(1) The majority of cases of postoperative recurrence involve distant metastasis with or without locoregional recurrence. Platinum-based systemic chemotherapy is practically accepted as the treatment for these diseases on the basis of evidence for original stage Ⅳ disease. The advent of both pemetrexed and molecular-targeted drugs has improved the survival of nonsquamous NSCLC and changed the chemotherapeutic algorithm for NSCLC;(2) Among patients with distant metastatic recurrence without locoregional recurrence at the primary tumor site, the metastasis is often limited in both organ and number. Such metastases are referred to as oligometastases. Local therapy, such as surgical resection and radiotherapy, has been suggested to be the first-line treatment of choice foroligometastatic recurrence; and(3) While locoregional recurrence is likely to cause troublesome symptoms, it is a potentially limited disease. Therefore, providing local control is important, and radiation is usually beneficial for treating local recurrence. In order to obtain better control of the disease and provide treatment with curative intent in patients with limited disease, the administration of concurrent platinum-based chemoradiotherapy is recommended according to the results of originally nonresectable stage ⅢA and ⅢB disease. | Tokujiro Yano Tatsuro Okamoto Seiichi Fukuyama Yoshihiko Maehara | 2014 | World Journal of Clinical Oncology2014，5，5： | 10 |
| 7 | Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis显示文摘A 69-year-old man was admitted to our hospital in October 2003,for further examination of two liver tumors.He was diagnosed with hepatocellular carcinoma(HCC) arising from decompensated hepatitis B virus(HBV)-related cirrhosis.Long-term lamivudine administration improved liver function dramatically despite repeated treatment for HCC.His Child-Pugh score was 9 points at start of lamivudine treatment,improving to 5 points after 1 year.His indocyanine green at 15 min after injection test score was 48%before lamivudine treat-ment,improving to 22%after 2 years and to 5%after 4 years.Radiofrequency ablation controlled the HCC foci and maintained his liver function.In April 2009,abdominal computed tomography revealed a tumor thrombus in the right portal vein.Since his indocyanine green test results had improved to less than 10%,we performed a right hepatectomy,which was successful.To our knowledge,there have been no documented reports of patients undergoing successful right hepatectomy for HCC arising from decompensated cirrhosis.The findings observed in our patient indicate the importance of nucleoside analogs for treating HBV-related HCC. | Koichi Honda Masataka Seike Shin-ichiro Maehara Koichiro Tahara Hideaki Anai Akira Moriuchi Toyokichi Muro | 2012 | World Journal of Gastroenterology2012，18，20： | 7 |
| 8 | The Relationship Between Attenuated Plaque Identified by Intravascular Ultrasound and No-Reflow After Stenting in Acute Myocardial Infarction显示文摘 | Xiaofan Wu Gary S. Mintz Kai Xu Alexandra J. Lansky Bernhard Witzenbichler Giulio Guagliumi Bruce Brodie Mirle A. Kellett Ovidiu Dressler Helen Parise Roxana Mehran Gregg W. Stone Akiko Maehara | 2011 | JACC: Cardiovascular Interventions2011，，5： | 3 |
| 9 | Rituximab, IVIG, and Plasma Exchange Without Graft Local Infusion Treatment: A New Protocol in ABO Incompatible Living Donor Liver Transplantation显示文摘 | Toru Ikegami Akinobu Taketomi Yuji Soejima Tomoharu Yoshizumi Hideaki Uchiyama Noboru Harada Tomohiro Iguchi Naotaka Hashimoto Yoshihiko Maehara | 2009 | Transplantation2009，，3： | 2 |
| 10 | Impact of Antithrombin III Concentrates on Portal Vein Thrombosis After Splenectomy in Patients With Liver Cirrhosis and Hypersplenism显示文摘 | Hirofumi Kawanaka Tomohiko Akahoshi Nao Kinjo Kozou Konishi Daisuke Yoshida Go Anegawa Shohei Yamaguchi Hideo Uehara Naotaka Hashimoto Norifumi Tsutsumi Morimasa Tomikawa Yoshihiko Maehara | 2010 | Annals of Surgery2010，，1： | 2 |
| 11 | Preoperative Neutrophil-to-Lymphocyte Ratio Is a Predictor of Survival After Hepatectomy for Hepatocellular Carcinoma: A Retrospective Analysis显示文摘 | Yohei Mano Ken Shirabe Yo-ichi Yamashita Norifumi Harimoto Eiji Tsujita Kazuki Takeishi Shinichi Aishima Toru Ikegami Tomoharu Yoshizumi Takeharu Yamanaka Yoshihiko Maehara | 2013 | Annals of Surgery2013，，2： | 2 |
| 12 | Tumor-Associated Macrophage Promotes Tumor Progression via STAT3 Signaling in Hepatocellular Carcinoma显示文摘 | Mano Yohei Aishima Shinichi Fujita Nobuhiro Tanaka Yuki Kubo Yuichiro Motomura Takashi Taketomi Akinobu Shirabe Ken Maehara Yoshihiko Oda Yoshinao | 2013 | Pathobiology2013，，3： | 2 |
| 13 | Priciple of Superplastic Diffusion Bonding显示文摘 | Maehara Y Komizo Y Langdon T G | 1988 | Materials Science and Technlogy1988，4，8： | 2 |
| 14 | One‐step venous reconstruction for a right lobe graft with multiple venous orifices in living donor liver transplantation显示文摘 | Yuji Soejima Naoyuki Ueda Takasuke Fukuhara Tomoharu Yoshizumi Toru Ikegami Yoichi Yamashita Keishi Sugimachi Akinobu Taketomi Yoshihiko Maehara | 2008 | Liver Transpl2008，，5： | 2 |
| 15 | Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer显示文摘 | Ryota Nakanishi Jun Harada Munkhbold Tuul Yan Zhao Koji Ando Hiroshi Saeki Eiji Oki Takefumi Ohga Hiroyuki Kitao Yoshihiro Kakeji Yoshihiko Maehara | 2013 | International Journal of Clinical Oncology2013，，6： | 2 |
| 16 | Prognostic Factors Affecting Survival at Recurrence of Hepatocellular Carcinoma After Living-Donor Liver Transplantation: With Special Reference to Neutrophil/Lymphocyte Ratio显示文摘 | Norifumi Harimoto Ken Shirabe Hidekazu Nakagawara Takeo Toshima Yo-ichi Yamashita Toru Ikegami Tomoharu Yoshizumi Yuji Soejima Tetsuo Ikeda Yoshihiko Maehara | 2013 | Transplantation Journal2013，，11： | 2 |
| 17 | A Simple Hilar Dissection Technique Preserving Maximum Blood Supply to the Bile Duct in Living Donor Liver Transplantation显示文摘 | Yuji Soejima Takasuke Fukuhara Kazutoyo Morita Tomoharu Yoshizumi Toru Ikegami Yoichi Yamashita Keishi Sugimachi Akinobu Taketomi Yoshihiko Maehara | 2008 | Transplantation2008，，10： | 2 |
| 18 | Role of tumor-associated macrophages in the progression of hepatocellular carcinoma显示文摘 | Ken Shirabe Yohei Mano Jun Muto Rumi Matono Takashi Motomura Takeo Toshima Kazuki Takeishi Hidekaki Uchiyama Tomoharu Yoshizumi Akinobu Taketomi Masaru Morita Shunichi Tsujitani Yoshihisa Sakaguchi Yoshihiko Maehara | 2012 | Surgery Today2012，，1： | 2 |
| 19 | Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer显示文摘AIM:To examine the methylation status of the promoter region of the checkpoint with forkhead-associated and ring fi nger(CHFR) and microsatellite mutator status in 59 primary gastric cancers.METHODS:We investigated the promoter methylation of CHFR in 59 cases of gastric cancer using methylation-specifi c PCR.Five microsatellite loci were analyzed using high-intensity microsatellite analysis reported previously, and p53 gene mutations were investigated by direct sequencing.RESULTS:Twenty cases(33.9%) showed promoter methylation and no relation was observed with the clinicopathological factors.We found that the promoter methylation of CHFR was frequently accompanied with microsatellite instability(MIN).Seven of 20(35.0%) cases showed MIN in hypermethylation of the CHFR tumor, while three of 39(7.7%) cases showed MIN in the non-methylated CHFR tumor(P < 0.01).However, we failed to fi nd any relationship between CHFR methylation and p53 mutation status.CONCLUSION:The coordinated loss of both the mitotic check point function and mismatch repair system suggests the potential to overcome the cell cycle check point, which may lead to an accumulation of mutations.However, the p53 mutation was not related to hypermethylation of the CHFR promoter and MIN, which indicates that an abnormality in p53 occurs as an independent process from the mismatch repair deficiency in carcinogenesis. | Eiji Oki Yan Zhao Rintaro Yoshida Takanobu Masuda Koji Ando Masahiiko Sugiyama Eriko Tokunaga Masaru Morita Yoshihiro Kakeji Yoshihiko Maehara | 2009 | World Journal of Gastroenterology2009，15，20： | 2 |
| 20 | Extended Indication for Living Donor Liver Transplantation in Patients With Hepatocellular Carcinoma显示文摘 | Yuji Soejima Akinobu Taketomi Tomoharu Yoshizumi Hideaki Uchiyama Shinich Aishima Takahiro Terashi Mitsuo Shimada Yoshihiko Maehara | 2007 | Transplantation2007，，7： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员